Skip to main
SIBN

SI-BONE Inc (SIBN) Stock Forecast & Price Target

SI-BONE Inc (SIBN) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

SI-BONE is well-positioned for growth and profitability, with a strong track record of revenue, GM, and EBITDA beats in the first quarter of 2026. The company's sales force model and partnership with SNN will likely drive continued growth, while potential reimbursement tailwinds and new product launches could further boost profitability. However, there are potential risks such as changes in reimbursement or competition that could impact the company's growth prospects.

Bears say

SI-BONE is facing downward pressure on ASPs due to fewer implants used in interventional and trauma procedures, potentially offset by continued outperformance in the SI Joint business. There is potential for upside in their guidance due to upcoming catalysts, including the SNN partnership and launch of a new product, but management has chosen to be conservative. Additionally, the company is experiencing productivity growth and has a partnership with Smith & Nephew that has yet to fully ramp up and contribute to revenue. However, the materiality of ESG factors can shift over time and may affect the company's performance.

SI-BONE Inc (SIBN) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About SI-BONE Inc (SIBN) Forecast

Analysts have given SI-BONE Inc (SIBN) a Strong Buy based on their latest research and market trends.

According to 6 analysts, SI-BONE Inc (SIBN) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

SI-BONE Inc (SIBN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.